Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer
Public ClinicalTrials.gov record NCT05113966. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This was a Phase 2, multicenter, open-label, single-arm study evaluating the safety and efficacy of trilaciclib administered prior to sacituzumab govitecan-hziy in participants with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) who received at least 2 prior treatments, at least 1 in the metastatic setting.
Study identification
- NCT ID
- NCT05113966
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 30 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 8, 2021 (Actual)
- Primary completion
- Nov 10, 2023 (Actual)
- Completion
- Jun 13, 2024 (Actual)
- Last update posted
- Jan 29, 2025
2021 – 2024
United States locations
- U.S. sites
- 22
- U.S. states
- 12
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ironwood Physicians | Chandler | Arizona | 85224 | — |
| Comprehensive Blood & Cancer Center | Bakersfield | California | 93309 | — |
| Los Angeles Hematology Oncology Medical Group | Los Angeles | California | 90017 | — |
| Valkyrie Clinical Trials | Los Angeles | California | 90067 | — |
| UCLA Hematology/Oncology Parkside | Santa Monica | California | 90404 | — |
| PIH Health | Whittier | California | 90602 | — |
| Rocky Mountain Cancer Centers | Denver | Colorado | 80220 | — |
| Memorial Healthcare System | Hollywood | Florida | 33021 | — |
| Orlando Health Cancer Institute | Orlando | Florida | 32806 | — |
| Duly Health and Care | Joliet | Illinois | 60435 | — |
| New England Cancer Specialists | Scarborough | Maine | 04704 | — |
| Minnesota Oncology Hematology, P.A. | Woodbury | Minnesota | 55125 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89128 | — |
| Northwest Cancer Specialists, PC | Tigard | Oregon | 97223 | — |
| Texas Oncology - Austin Central | Austin | Texas | 78731 | — |
| Texas Oncology - Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Texas Oncology - Longview Cancer Center | Longview | Texas | 75601 | — |
| Inova Schar Cancer Institute | Fairfax | Virginia | 22031 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
| Oncology and Hematology Associates of Southwest Virginia, Inc | Roanoke | Virginia | 24014 | — |
| Multicare Health System | Auburn | Washington | 98001 | — |
| Northwest Medical Specialties, PLLC | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05113966, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 29, 2025 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05113966 live on ClinicalTrials.gov.